Published in J Nucl Med on December 21, 2012
Reply: To PMID 22343504. J Nucl Med (2013) 0.75
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Inverse consistent mapping in 3D deformable image registration: its construction and statistical properties. Inf Process Med Imaging (2005) 2.87
Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 2.80
Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci (2009) 2.78
Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab (2005) 2.52
Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med (2007) 1.85
Dorsal striatal D2-like receptor availability covaries with sensitivity to positive reinforcement during discrimination learning. J Neurosci (2011) 1.82
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med (2006) 1.74
Tight glycemic control increases metabolic distress in traumatic brain injury: a randomized controlled within-subjects trial. Crit Care Med (2012) 1.62
Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med (2010) 1.57
Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med (2003) 1.57
Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging. Eur Radiol (2010) 1.54
Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol (2006) 1.52
Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data. J Nucl Med (2007) 1.42
Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med (2004) 1.37
Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A (2006) 1.34
Effects of administration route, dietary condition, and blood glucose level on kinetics and uptake of 18F-FDG in mice. J Nucl Med (2011) 1.31
In vivo quantitation of glucose metabolism in mice using small-animal PET and a microfluidic device. J Nucl Med (2007) 1.30
Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry (2002) 1.30
Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med (2010) 1.27
18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging (2007) 1.25
Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest (2006) 1.23
Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med (2005) 1.23
1-11C-acetate kinetics of prostate cancer. J Nucl Med (2008) 1.20
Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med (2011) 1.18
18F-FDOPA kinetics in brain tumors. J Nucl Med (2007) 1.18
3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med (2011) 1.18
Noninvasive measurement of myocardial activity concentrations and perfusion defect sizes in rats with a new small-animal positron emission tomograph. Circulation (2002) 1.18
Quantification of cerebral glucose metabolic rate in mice using 18F-FDG and small-animal PET. J Nucl Med (2009) 1.17
Noninvasive measurement of cardiovascular function in mice with high-temporal-resolution small-animal PET. J Nucl Med (2006) 1.14
Accuracy of a method using short inhalation of (15)O-O(2) for measuring cerebral oxygen extraction fraction with PET in healthy humans. J Nucl Med (2004) 1.13
Selective metabolic reduction in gray matter acutely following human traumatic brain injury. J Neurotrauma (2004) 1.09
Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur J Nucl Med Mol Imaging (2009) 1.08
Brain tumors. Semin Nucl Med (2012) 1.05
Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol (2010) 1.04
Radiation dose estimates in humans for (11)C-acetate whole-body PET. J Nucl Med (2004) 1.04
Improved parametric image generation using spatial-temporal analysis of dynamic PET studies. Neuroimage (2002) 1.04
Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning. J Biol Chem (2010) 1.03
Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med (2010) 1.02
Visualizing pathology deposits in the living brain of patients with Alzheimer's disease. Methods Enzymol (2006) 1.02
Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans. J Nucl Med (2010) 1.01
Correlation of regional metabolic rates of glucose with glasgow coma scale after traumatic brain injury. J Nucl Med (2003) 1.01
Acute changes in regional cerebral (18)F-FDG kinetics in patients with traumatic brain injury. J Nucl Med (2004) 1.01
FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging (2002) 0.99
Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur J Nucl Med Mol Imaging (2010) 0.99
Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J Nucl Med (2009) 0.99
Dissecting molecular mechanisms in the living brain of dementia patients. Acc Chem Res (2009) 0.98
Subcortical white matter metabolic changes remote from focal hemorrhagic lesions suggest diffuse injury after human traumatic brain injury. Neurosurgery (2004) 0.97
Determinants of myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans. Eur J Nucl Med Mol Imaging (2006) 0.97
Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry (2009) 0.97
Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest (2005) 0.96
Assessment of intra- and interobserver reproducibility of rest and cold pressor test-stimulated myocardial blood flow with (13)N-ammonia and PET. Eur J Nucl Med Mol Imaging (2007) 0.95
PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction. Eur J Nucl Med Mol Imaging (2006) 0.94
Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease. Arch Gen Psychiatry (2006) 0.94
Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol (2005) 0.94
PET of brain prion protein amyloid in Gerstmann-Sträussler-Scheinker disease. Brain Pathol (2009) 0.93
The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med (2002) 0.93
Semiautomated analysis of small-animal PET data. J Nucl Med (2006) 0.91
PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis (2013) 0.91
Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis (2013) 0.90
Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone (2011) 0.90
PPARγ silencing enhances osteogenic differentiation of human adipose-derived mesenchymal stem cells. J Cell Mol Med (2013) 0.88
Influence of dietary state and insulin on myocardial, skeletal muscle and brain [F]-fluorodeoxyglucose kinetics in mice. EJNMMI Res (2011) 0.88
Redefining the pericontusional penumbra following traumatic brain injury: evidence of deteriorating metabolic derangements based on positron emission tomography. J Neurotrauma (2013) 0.87
2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol (2003) 0.87
Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res (2011) 0.87
Diagnostic value of PET-measured heterogeneity in myocardial blood flows during cold pressor testing for the identification of coronary vasomotor dysfunction. J Nucl Cardiol (2007) 0.86
Evaluation of metastatic meningioma with 2-deoxy-2-[18F]fluoro-D-glucose PET/CT. Clin Nucl Med (2005) 0.85
[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment. Neurobiol Dis (2011) 0.85
MAP reconstruction for Fourier rebinned TOF-PET data. Phys Med Biol (2014) 0.84
Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol (2012) 0.83
In vivo brain imaging of tangle burden in humans. J Mol Neurosci (2002) 0.82
Positron emission tomography imaging of DMBA/TPA mouse skin multi-step tumorigenesis. Mol Oncol (2010) 0.82
Exploring a mathematical model for the kinetics of beta-amyloid molecular imaging probes through a critical analysis of plaque pathology. Mol Imaging Biol (2006) 0.81
Measurement of the global lumped constant for 2-deoxy-2-[18F]fluoro-D-glucose in normal human brain using [15O]water and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography imaging. A method with validation based on multiple methodologies. Mol Imaging Biol (2003) 0.81
NEC: some coincidences are more equivalent than others. J Nucl Med (2005) 0.81
Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images. J Nucl Med (2004) 0.81
Evaluation of the Genisys4, a bench-top preclinical PET scanner. J Nucl Med (2013) 0.81
Predicting seizure-free status for temporal lobe epilepsy patients undergoing surgery: prognostic value of quantifying maximal metabolic asymmetry extending over a specified proportion of the temporal lobe. J Nucl Med (2007) 0.80
Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging. J Alzheimers Dis (2013) 0.80
Automated VOI Analysis in FDDNP PET Using Structural Warping: Validation through Classification of Alzheimer's Disease Patients. Int J Alzheimers Dis (2012) 0.80
A hybrid clustering method for ROI delineation in small-animal dynamic PET images: application to the automatic estimation of FDG input functions. IEEE Trans Inf Technol Biomed (2010) 0.80
Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor. J Nucl Med (2009) 0.80
Prediction of cognitive decline based on hemispheric cortical surface maps of FDDNP PET. Neuroimage (2012) 0.79